Microbes To Molecules
Pharmabiotics are any biological entity ‘mined’ from the gastrointestinal microbiota, including probiotics, bacteriocins, bacteriophages and bioactive molecules, and these are at the heart of the “Microbes to Molecules” theme. We believe that pharmabiotics will make significant impacts in the pharmaceutical, medical food and functional food sectors. For example, the current threat posed by multi-drug resistant bacteria is a major challenge. The APC Microbiome Institute has discovered, patented and licenced a narrow spectrum antimicrobial highly active against Clostridium difficile, while bacteriophages active against Pseudomonas aeruginosahave also been patented. We have also patented antimicrobial technologies for the animal husbandry sector against Salmonella and mastitis.
The APC has discovered, patented and licenced a narrow spectrum antimicrobial highly active against Clostridium difficile, while bacteriophages active against Pseudomonas aeruginosa have also been patented. Outputs from this theme will include new anti-inflammatory and anti-infective therapeutics. We will also develop functional ingredients for the food sector and will assist food companies to provide sufficient scientific and clinical validation to address health claim requirements of EFSA and other regulatory bodies.